PMID- 30088203
OWN - NLM
STAT- MEDLINE
DCOM- 20191010
LR  - 20210420
IS  - 1179-1934 (Electronic)
IS  - 1172-7047 (Linking)
VI  - 32
IP  - 8
DP  - 2018 Aug
TI  - Amantadine Extended-Release (GOCOVRI()): A Review in Levodopa-Induced Dyskinesia 
      in Parkinson's Disease.
PG  - 797-806
LID - 10.1007/s40263-018-0552-2 [doi]
AB  - Amantadine extended-release (ER) capsules (GOCOVRI()) are approved in the USA 
      for the treatment of dyskinesia in patients with Parkinson's disease (PD) 
      receiving levodopa-based therapy, with or without concomitant dopaminergic 
      medications. With a recommended dosage of 274 mg once daily at bedtime, this new 
      formulation of amantadine allows a more gradual time to peak plasma amantadine 
      concentration and higher drug concentrations in the morning and throughout the 
      day, the time period when levodopa-induced dyskinesia (LID) is the most 
      problematic. In 13-week (EASE LID 3) and 25-week (EASE LID), randomized, 
      double-blind phase III trials, once-daily amantadine ER 274 mg capsules 
      significantly improved levodopa-induced dyskinesia (LID), while also increasing 
      ON time without troublesome dyskinesia and reducing OFF time and ON time with 
      troublesome dyskinesia from the morning and throughout the day, compared with 
      placebo. In the ongoing, longer-term EASE LID 2 study (with interim results 
      reported for up to 64 weeks), patients previously treated with amantadine ER 
      maintained improvements in LID, as per patient-reported Unified Dyskinesia Rating 
      Scale (UDysRS) scoring and ON/OFF times. Amantadine ER was generally well 
      tolerated, with most adverse events (AEs) being transient and mild or moderate in 
      severity. The most common (incidence > 15%) treatment-related AEs in the 
      placebo-controlled trials were hallucinations, dizziness, dry mouth and 
      peripheral oedema. While long-term data are needed to establish durability of 
      response and safety, including the completion of the  approximately  2-year EASE LID 2 study, 
      current evidence indicates that amantadine ER is an effective treatment option to 
      consider in the management of LID in PD patients.
FAU - Paik, Julia
AU  - Paik J
AD  - Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. 
      demail@springer.com.
FAU - Keam, Susan J
AU  - Keam SJ
AD  - Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - CNS Drugs
JT  - CNS drugs
JID - 9431220
RN  - 0 (Antiparkinson Agents)
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Dopamine Agents)
RN  - 46627O600J (Levodopa)
RN  - BF4C9Z1J53 (Amantadine)
SB  - IM
MH  - Amantadine/*administration & dosage
MH  - Animals
MH  - Antiparkinson Agents/adverse effects
MH  - Delayed-Action Preparations/*therapeutic use
MH  - Dopamine Agents/*administration & dosage
MH  - Dyskinesia, Drug-Induced/*drug therapy/etiology
MH  - Humans
MH  - Levodopa/adverse effects
MH  - Parkinson Disease/drug therapy
EDAT- 2018/08/09 06:00
MHDA- 2019/10/11 06:00
CRDT- 2018/08/09 06:00
PHST- 2018/08/09 06:00 [pubmed]
PHST- 2019/10/11 06:00 [medline]
PHST- 2018/08/09 06:00 [entrez]
AID - 10.1007/s40263-018-0552-2 [pii]
AID - 10.1007/s40263-018-0552-2 [doi]
PST - ppublish
SO  - CNS Drugs. 2018 Aug;32(8):797-806. doi: 10.1007/s40263-018-0552-2.